Answers are grounded in this paper and cite their sources.
A total of 77 literatures till November 2020 were screened regarding various interventions to treat COVID-19patients, among which 16 and 15 studies fulfilling predefined exclusion and inclusion criteria were subjected toPairwise and Network meta-analysis respectively. In Pairwise meta-analysis, the recovery rate of treatment withLopinavir/Ritonavir versus other antiviral (OR= 0. 0381, CI= 0.0021-0.6870), placebo (OR= 0.6592, CI= 0.4207-1.0329), Remdesivir (OR= 0.5286, CI= 0.3915-0.7137) and standard care (OR= 0.9787, CI= 0.8523-1.1238) in fixedand random effect model with 95% confidence limit found statistically significant protection than those of allother treatment. In Network meta-analysis, recovery estimates sizes of treatment, in reference with other antivirals1.0000 (0.9917, 1.0000) shows less risk with treatment Standard care 0.7811 (0.6696, 0.8417), Remdesivir 0.7717(0.6491, 0.8144), Lopinavir/ Ritonavir 0.7801 (0.6701, 0.8473), Placebo 0.7219 (0.6178, 0.7836).
No takes yet. Share an insight, caveat, or question.
Singh et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: